We have located links that may give you full text access.
Quantitative assessment of FDG uptake in brown fat using standardized uptake value and dual-time-point scanning.
Clinical Nuclear Medicine 2008 October
OBJECTIVES: Brown fat is a potential source of false-positive findings on FDG PET. The purpose of this study was to show the variability in body distribution of brown fat, the degree of FDG uptake, the changes on dual-time-point scanning, and determine if dual-time-point scanning can help in differentiating brown fat from malignant lesions.
METHODS: Thirty-two patients were included in this retrospective study (14 male, 18 female, age range: 8-72 years). All patients had hypermetabolic brown fat activity on FDG PET imaging confirmed by computed tomography (CT) scanning. All patients underwent 2 sequential FDG PET scanning (dual-time-point imaging). The average percent change in maximum standardized uptake value (SUVmax) for 120 brown fat spots between time point 1 and time point 2 was calculated.
RESULTS: Body distribution of hypermetabolic brown fat in the 32 patients included supraclavicular area (n = 7); cervical and supraclavicular (n = 5); cervical, supraclavicular, and axillae (n = 5); cervical area, supraclavicular, axillae, and paravertebral (n = 8); supraclavicular, cervical, axillae, paravertebral, and mediastinum (n = 4); supraclavicular, cervical, axillae, paravertebral, and upper abdomen (n = 2); and supraclavicular, cervical, axillae, paravertebral, mediastinum, and intercostals (n = 1). SUVmax for brown fat spots ranged from 0.8 to 12.4 and mean SUV was 4.6 + 1.6. On dual-time-point imaging, 91 (76%) of the brown fat spots demonstrated an increase in SUVmax that ranged from 12% to 192% and mean value of 42%, whereas 16 (13%) brown fat spots did not show any change and 11 (11%) spots underwent a drop in SUVmax by 4% to 12%. There was an increase in the number of active brown fat spots in 3 patients on the second time images.
CONCLUSIONS: Brown fat is a potential source of false positives, which has wide variability in distribution and degree of FDG uptake. On dual-time-point scanning, there is a progressive increase in FDG uptake within most of the hypermetabolic brown fat areas that mimic malignant lesions.
METHODS: Thirty-two patients were included in this retrospective study (14 male, 18 female, age range: 8-72 years). All patients had hypermetabolic brown fat activity on FDG PET imaging confirmed by computed tomography (CT) scanning. All patients underwent 2 sequential FDG PET scanning (dual-time-point imaging). The average percent change in maximum standardized uptake value (SUVmax) for 120 brown fat spots between time point 1 and time point 2 was calculated.
RESULTS: Body distribution of hypermetabolic brown fat in the 32 patients included supraclavicular area (n = 7); cervical and supraclavicular (n = 5); cervical, supraclavicular, and axillae (n = 5); cervical area, supraclavicular, axillae, and paravertebral (n = 8); supraclavicular, cervical, axillae, paravertebral, and mediastinum (n = 4); supraclavicular, cervical, axillae, paravertebral, and upper abdomen (n = 2); and supraclavicular, cervical, axillae, paravertebral, mediastinum, and intercostals (n = 1). SUVmax for brown fat spots ranged from 0.8 to 12.4 and mean SUV was 4.6 + 1.6. On dual-time-point imaging, 91 (76%) of the brown fat spots demonstrated an increase in SUVmax that ranged from 12% to 192% and mean value of 42%, whereas 16 (13%) brown fat spots did not show any change and 11 (11%) spots underwent a drop in SUVmax by 4% to 12%. There was an increase in the number of active brown fat spots in 3 patients on the second time images.
CONCLUSIONS: Brown fat is a potential source of false positives, which has wide variability in distribution and degree of FDG uptake. On dual-time-point scanning, there is a progressive increase in FDG uptake within most of the hypermetabolic brown fat areas that mimic malignant lesions.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app